Tuesday, April 16, 2024
Labcorp, a renowned provider of advanced laboratory services, has recently introduced a groundbreaking blood test aimed at detecting glial fibrillary acidic protein (GFAP), a crucial biomarker associated with the early stages of neurodegenerative diseases and brain injuries. This innovative GFAP test, now available across the nation, represents a significant advancement in the field, offering healthcare professionals a more efficient means of identifying conditions such as Alzheimer's disease, multiple sclerosis, glioblastoma, and traumatic brain injury (TBI) in their initial phases.
The addition of the GFAP test enriches Labcorp's extensive neurology portfolio, complementing existing biomarker tests for neurofilament light chain (NfL), pTau181, pTau217, and beta amyloid 42/40. Leveraging highly sensitive immunoassay technology, the GFAP test accurately measures GFAP levels in the blood, providing a convenient and accessible diagnostic tool for healthcare providers and patients alike.
GFAP, predominantly found in astrocytes—the support cells of the brain—is released into the bloodstream following neurological damage, making it a valuable early indicator of such conditions. Labcorp's introduction of the GFAP test underscores its commitment to advancing diagnostic capabilities in the realm of neurodegenerative diseases and brain injuries, further solidifying its position as a leader in the field of medical diagnostics.
Source: prnewswire.com
